After hours: 4:26PM EDT
|Bid||47.30 x 1100|
|Ask||52.00 x 1000|
|Day's Range||47.62 - 48.10|
|52 Week Range||40.78 - 56.28|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||13.54|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SWINDON, United Kingdom, Feb. 18, 2019 -- Sensata Technologies (NYSE: ST) today announced that Martha Sullivan, CEO, will present at the Barclays Industrial Select Conference.
SWINDON, United Kingdom, Feb. 06, 2019 -- Sensata Technologies (NYSE: ST), a global industrial technology company and a leading provider of sensors, today announced financial.
Sensata Technologies (ST), an industrial technology company and a leading provider of sensors, today announced that John Absmeier, Chief Technology Officer of Lear Corporation, has been appointed to serve as a director on Sensata’s Board of Directors and to serve on the Growth & Innovation Committee of the Board, each effective March 1, 2019. As Chief Technology Officer of Lear Corporation, Mr. Absmeier leads all aspects of Lear’s technology and innovation efforts, reporting to the company’s President and Chief Executive Officer.
SWINDON, United Kingdom, Jan. 15, 2019 -- Sensata Technologies (NYSE:ST) today announced that it will disclose its fourth quarter and full year 2018 financial results on.
The Sensata Technologies Foundation, launched in November 2017, announced its first annual grant award recipients for funding year 2019. The Foundation also announced that the grant application for the 2019-2020 grant cycle is now available on the Sensata Foundation website and will close on Friday, June 28, 2019. The Sensata Foundation’s Annual Grants are 12-month grants for new or existing projects related to one or more of the Foundation’s priorities of STEM and Community.
SWINDON, United Kingdom, Oct. 30, 2018 -- Sensata Technologies (NYSE:ST), a global industrial technology company and a leading provider of sensors, today announced financial.
Medical Prognosis Institute A/S and Oncology Venture AB (ST) ("OV" or the "Company") and Oncology Venture US Inc today announced that the US Food and Drug Administration (FDA) has accepted its Investigational Device Exemption (IDE) and its Investigational New Drug Application (IND) to begin a Phase 2 clinical trial in advanced ovarian cancer with 2X-121 -a PARP inhibitor- using it`s Drug Response Predictor - DRP - to select patients with high likelihood of responding to the treatment. The 2X-121 DRP has a gene signature consisting of more than 400 genes.
NEW YORK, NY / ACCESSWIRE / July 24, 2018 / Sensata Technologies Holding plc (NYSE: ST ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 24, 2018 at 8:00 AM Eastern ...
Hoersholm, Denmark, June 28, 2018 -Medical Prognosis Institute A/S (ST) and Oncology Venture AB (ST) announces that the Office of Orphan Products Development at the FDA has transferred the Dovitinib Orphan drug designation for the treatment of adenoid cystic carcinoma to Oncology Venture from Novartis. Dovitinib is an oral available phase 3 multi Tyrosine Kinase Inhibitor (previously TKI258), for which OV holds the exclusive global rights for development and commercialization. OV is developing the dovitinib Drug Response predictor DRP® based on existing data from patient`s biopsies and clinical outcome.
Medical Prognosis Institute A/S (ST), Oncology Venture AB (ST) and Oncology Venture US Inc. (former 2X Oncology Inc.) announces dosing of the first patient in a Phase 2, clinical study to investigate the anti-tumor effect and tolerability of 2X-121 in patients with metastatic breast cancer selected by a novel drug response predictor (DRP®) mRNA driven multiple biomarker, the 2X-121 DRP®. 2X-121 is a PARP inhibitor. This clinical trial will enroll metastatic Breast Cancer patients , who have relapsed on two or more different prior therapies.
Ahead of today's trading session, WallStEquities.com has selected the following stocks for monitoring: MKS Instruments Inc. (NASDAQ: MKSI), Orbotech Ltd (NASDAQ: ORBK), Sensata Technologies Holding PLC (NYSE: ST), and Trimble Inc. (NASDAQ: TRMB). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Thursday, May 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Scientific & Technical Instruments equities this morning: Keysight Technologies Inc. (NYSE: KEYS), MKS Instruments Inc. (NASDAQ: MKSI), Sensata Technologies Holding PLC (NYSE: ST), and Trimble Inc. (NASDAQ: TRMB).